| Name | Title | Contact Details |
|---|---|---|
liakatali Bodalbhai |
Director R&D | Profile |
Liakat Bodalbhai |
Director R&D | Profile |
Virjinia Cortez |
Director, R&D Development Services | Profile |
Frank Sorgi |
VP of R&D | Profile |
DiaMedica Inc., a development stage biopharmaceutical company, is engaged in the discovery and development of drugs for the treatment of diabetes and related diseases. The company`s lead clinical stage compound is DM199, a recombinant human protein known as rhKLK1, which is under phase I/II clinical trials for the treatment of Type 1 and Type 2 diabetes and associated complications. It is also developing DM204, a monoclonal antibody that is in preclinical development for the treatment of Type 2 diabetes; and DMDx, a chronic kidney disease assay to detect levels of the tissue kallikrein-1 protein in urine and to predict the rate of kidney disease progression. The company was formerly known as Diabex Inc. and changed its name to DiaMedica Inc. in February 2001. DiaMedica Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.
Advance with TriRx. Your contract development & manufacturing organization focused on non-sterile & sterile products, animal health injectables & packaging.
Paramount Pharmacies Limited is a New Waterford, NS-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
SJLABS is a Solon, OH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Merus is developing best-in-class therapeutics to treat and potentially cure cancer patients. Our most advanced development programs use the Biclonics® format. Biclonics® are capable of simultaneously attacking tumors in multiple ways. For example by activating the immune system to kill tumor cells and directly inhibiting tumor cell growth and survival pathways.